Sodium Stibogluconate Property

Melting point:

>250°C (dec,)

storage temp. 

2-8°C

solubility 

H₂O: 1 mg/mL at ~75 °C

form 

solid

color 

pale yellow

Stability:

Hygroscopic

InChIKey

VJCZMGLJTJZFEN-ZYPIZMQFSA-K

CAS DataBase Reference

16037-91-5

Safety

Hazard Codes 

Xn,N

Risk Statements 

20/22-51/53

Safety Statements 

61

RIDADR 

3282

WGK Germany 

3

RTECS 

CC7930000

HazardClass 

6.1(b)

PackingGroup 

III

Toxicity

LD50 ipr-mus: 33 mg/kg CLDND* 11,155,49

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H411Toxic to aquatic life with long lasting effects

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P273Avoid release to the environment.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

Sodium Stibogluconate Chemical Properties,Usage,Production

Description

Sodium stibogluconate is a pentavalent antimony derivative that is highly active against Leishmania amastigotes in macrophages. Sodium stibogluconate has diverse effects on both this intracellular parasite and its host cell.

Uses

Sodium Stibogluconate is an intermediate used to prepare Dihydropyrido[2,3-d]pyrimidines as a new class of antileishmanial agents.

Uses

Sodium stibogluconate is a pentavalent antimony derivative that is highly active against Leishmania amastigotes in macrophages. Sodium stibogluconate has diverse effects on both this intracellular parasite and its host cell.

Antimicrobial activity

It has low activity against the extracellular promastigote stage of Leishmania spp. in vitro, but is active against amastigotes in macrophages. The trivalent form is considered to be the toxophore, with metabolism of Sb^V to toxic Sb^III in the host cell macrophage and the parasite; the level of metabolism is higher in amastigotes than promastigotes. Variation in the sensitivity of different Leishmania species may contribute to differences in clinical response. It is more active against visceral than cutaneous leishmaniasis in animal models. Sodium stibogluconate cures CNS infections with T. brucei in rodents.

Acquired resistance

Unresponsiveness and relapse of L. donovani infections in Bihar State, India (over 60% of cases), is due to increasing acquired resistance. In laboratory-generated and clinical isolates, resistant Leishmania promastigotes show increased levels of intracellular thiols, for example trypanothione, to which Sb^III is conjugated and extruded by efflux pumps.
Lack of response is also reported in patients with mucosal leishmaniasis caused by L. braziliensis. Relapse is common in patients with visceral leishmaniasis who are immunosuppressed, for example by HIV infection, but this is due to pathogen interaction and the immune dependence of drug activity and not acquired resistance. High mortality has been reported in treatment of these co-infection cases.

Pharmaceutical Applications

A pentavalent antimonial of uncertain chemical composition; probably a complex mixture of polymeric forms. There is batchto- batch variation and solutions may contain 32–34% pentavalent antimony (Sb^V). The structural formula is conjectural as studies have identified a mixture of non-complexed Sb^V and large polymeric gluconate complexes. Chemical composition also depends on concentration and time. It is freely soluble in water.

Pharmacokinetics

Peak concentrations of about 12–15 mg antimony/L are achieved in serum 1 h after a dose of 10 mg/kg. There is a slow accumulation in the central compartment, and tissue concentrations reach a maximum after several days. In contrast to trivalent derivatives, pentavalent antimonials are not accumulated by erythrocytes, but there is evidence of protein binding. Antimony is detected in the skin for at least 5 days after treatment. Some of the dose of Sb^V is converted to Sb^III, possibly by the liver or by macrophages. It is rapidly excreted into urine with a half-life of about 2 h; 60–80% of the dose appears in the urine within 6 h of parenteral administration. In a study on structurally related meglumine antimonate the pharmacokinetics of Sb^V and SbIII were similar as measured by serum and urine levels.

Clinical Use

Sodium antimony gluconate (Pentostam) is a pentavalent antimonialcompound intended primarily for the treatment ofvarious forms of leishmaniasis. It is available from the CDCas the disodium salt, which is chemically stable and freelysoluble in water. The 10% aqueous solution used for eitherintramuscular or intravenous injection has a pH of approximately5.5. Like all antimonial drugs, this drug has a lowtherapeutic index, and patients undergoing therapy with itshould be monitored carefully for signs of heavy metal poisoning.Other organic antimonial compounds are used primarilyfor the treatment of schistosomiasis and other flukes.The antileishmanial action of sodium stibogluconate requiresits reduction to the trivalent form, which is believedto inhibit phosphofructokinase in the parasite.

Clinical Use

Visceral, cutaneous and mucocutaneous leishmaniasis
The combination with paromomycin has been used in unresponsive cases and in relapses of visceral and cutaneous leishmaniasis.

Side effects

The toxic effects are limited by the rapid excretion, but cumulative toxicity increases in proportion to dose. Myalgia, arthralgia, anorexia and electrocardiographic changes have been reported with high-dose regimens. In particular, development of ventricular tachyarrhythmias associated with prolongation of the QT interval has been recorded. Hepatocellular damage, hepatic and renal functional impairment and pancreatitis have also been reported. The changes are reversible on discontinuation of treatment.

Safety Profile

Poison by intraperitoneal route. When heated to decomposition it emits toxic fumes of Sb.

Veterinary Drugs and Treatments

Sodium stibogluconate is used for the treatment of leishmaniasis in dogs.

Drug interactions

otentially hazardous interactions with other drugs
P Antifungals: possible increased risk of arrhythmias with amphotericin - give 14 days apart.

Metabolism

No data on possible metabolic pathways.
Elimination occurs in two phases; a rapid initial phase, in which the majority of a dose is excreted via the kidneys within 12 hours, and a slower phase, possibly reflecting reduction to trivalent antimony.